Novel Complement C5 Small-interfering RNA Lipid Nanoparticle Prolongs Graft Survival in a Hypersensitized Rat Kidney Transplant Model-Reference-Cited by-同舟云学术

Novel Complement C5 Small-interfering RNA Lipid Nanoparticle Prolongs Graft Survival in a Hypersensitized Rat Kidney Transplant Model

Published:2022-11-22 Issue:12 Volume:106 Page:2338-2347
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Ishigooka Hidetoshi,Katsumata Haruki,Saiga Kan,Tokita Daisuke,Motoi Sotaro,Matsui Chiyuki,Suzuki Yuta,Tomimatsu Ayaka,Nakatani Tomoya,Kuboi Yoshikazu,Yamakawa Takafumi,Ikeda Takashi,Ishii Rumi,Imai Toshio,Takagi Toshio,Tanabe Kazunari

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference63 articles.

1. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine.;Wang;Transplantation,2005

2. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation.;Wang;J Immunol,2007

3. C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients.;Rother;Am J Transplant,2008

4. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.;Hillmen;N Engl J Med,2004

5. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.;Hillmen;N Engl J Med,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoparticle-assisted Targeting Delivery Technologies for Preventing Organ Rejection;Transplantation;2024-04-08

2. The Promise of Complement Therapeutics in Solid Organ Transplantation;Transplantation;2024-02-16

3. Development of the Complement C5 Assay by LC–MS/MS in Monkey Serum and Comparison with Enzyme-Linked Immunosorbent Assay;ACS Omega;2024-01-31

4. Differences and Similarities of the Intravenously Administered Lipid Nanoparticles in Three Clinical Trials: Potential Linkage between Lipid Nanoparticles and Extracellular Vesicles;Molecular Pharmaceutics;2023-09-17

5. Lipid nanoparticle-targeted mRNA formulation as a treatment for ornithine-transcarbamylase deficiency model mice;Molecular Therapy - Nucleic Acids;2023-09